{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04396899",
      "OrgStudyIdInfo": {
        "OrgStudyId": "02289"
      },
      "Organization": {
        "OrgFullName": "University Medical Center Goettingen",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure",
      "OfficialTitle": "Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure",
      "Acronym": "BioVAT-HF"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 3, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 2024",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 11, 2020",
      "StudyFirstSubmitQCDate": "May 15, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 21, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "February 18, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 21, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Karsten Gavenis",
        "ResponsiblePartyInvestigatorTitle": "on behalf of Principal Investigator Prof. Seidler",
        "ResponsiblePartyInvestigatorAffiliation": "University Medical Center Goettingen"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University Medical Center Goettingen",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "University Medical Center Freiburg",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The BioVAT-HF trial will test the hypothesis that cardiomyocyte implantation via engineered heart muscle (EHM), the proposed investigational medicinal product (IMP; designated \"Biological Ventricular Assist Tissue\" or BioVAT), results in sustainable remuscularization and biological enhancement of myocardial performance in the failing heart. EHM are constructed from defined mixtures of induced pluripotent stem cell (iPSC)-derived cardiomyocytes and stromal cells in a bovine collagen type I hydrogel. Comprehensive preclinical testing confirmed the rationale for the clinical translation of the myocardial remuscularization strategy by EHM implantation. The patient target population for EHM therapy is patients suffering from advanced heart failure with reduced ejection fraction (HFrEF; EF: ≤35%) and no realistic option for heart transplantation."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Heart Failure"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "53",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "EHM Implantation",
            "ArmGroupType": "Other",
            "ArmGroupDescription": "All patients will receive EHM implant",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: EHM implantation"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "EHM implantation",
            "InterventionDescription": "Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF <35%).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "EHM Implantation"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Target heart wall thickness",
            "PrimaryOutcomeDescription": "Target heart wall thickness (HWT) as determined by high resolution echocardiography and/or CINE-mode MRI (17-segment model). Primary efficacy analyses are based on the changes in HWT between baseline and 2 weeks, 1 month, 3 months, 6 months and 12 months after implantation. To test for a time effect a one-way Repeated Measures ANOVA will be performed for the primary endpoint. In case of detecting a time effect this is followed by Dunnett-type pairwise comparisons to baseline using paired t-Tests. Due to the explorative character of the efficacy analysis testing will be performed at a 10% two-sided significance level. Mean differences will be reported along with 90% confidence intervals.",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Heart wall thickening fraction",
            "PrimaryOutcomeDescription": "Heart wall thickening fraction (HWTF) as determined by high resolution echocardiography and/or CINE-mode MRI (17-segment model). Primary efficacy analyses are based on the changes in HWTF between baseline and 2 weeks, 1 month, 3 months, 6 months and 12 months after implantation. To test for a time effect a one-way Repeated Measures ANOVA will be performed for the primary endpoint. In case of detecting a time effect this is followed by Dunnett-type pairwise comparisons to baseline using paired t-Tests. Due to the explorative character of the efficacy analysis testing will be performed at a 10% two-sided significance level. Mean differences will be reported along with 90% confidence intervals.",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nHFrEF (EF ≤ 35%) as assessed by high-resolution echocardiography or MRI\nNo realistic chance or not eligible for heart transplantation\nAt least one hypo- or dyskinetic segment to demark the implant target area\nStable disease condition allowing for an elective left-lateral mini-thoracotomy (for LV applications) or open-chest surgery (for RV applications) for a clinically indicated intervention on the LV (e.g., coronary bypass surgery, valve repair) with concomitant RV dysfunction, diagnosed using the Tricuspid Annular Plane Systolic Excursion (TAPSE) index <16 mm (Rudski et al. 2010).\n18-80 years of age\nPrevious implantation of an ICD or CRT-D with event recorder\nNew York Heart Association (NYHA) Class III or IV under optimal medical therapy\nWillingness and ability to give written informed consent\nFemale subjects of childbearing potential must agree to use acceptable method(s) of contraception for the full study duration.\n\nExclusion Criteria:\n\nContraindication to immunosuppressive drugs (e.g. known history of unresolved cancer, hepatitis B/C, HIV, HTLV1)\nAlloimmunisation against EHM implant cells\nHypertrophic cardiomyopathy (HCM)\nTerminal kidney failure (stage 4; GFR <30 ml/min)\nTerminal liver failure\nAutoimmune disease\nHistory of stroke\nReduced life expectancy in the short term due to non-cardiac disease\nSimultaneous participation in another interventional trial\nPregnant or breastfeeding females\nKnown or suspected alcohol and/or drug abuse",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Wolfram-Hubertus Zimmermann, Prof.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+49 551 / 3965781",
            "CentralContactEMail": "sekretariat.pharma@med.uni-goettingen.de"
          },
          {
            "CentralContactName": "Florian Walker, Dr.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+49 551 / 3960825",
            "CentralContactEMail": "florian.walker@med.uni-goettingen.de"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Tim Seidler, Prof.",
            "OverallOfficialAffiliation": "University Medical Center Goettingen",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University Medical Center Göttingen",
            "LocationStatus": "Recruiting",
            "LocationCity": "Göttingen",
            "LocationState": "Lower Saxony",
            "LocationZip": "37075",
            "LocationCountry": "Germany",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Tim Seidler, Prof.",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          },
          {
            "LocationFacility": "Herz- und Diabeteszentrum Nordrhein-Westfalen",
            "LocationStatus": "Not yet recruiting",
            "LocationCity": "Bad Oeynhausen",
            "LocationState": "North Rhine-Westphalia",
            "LocationZip": "32545",
            "LocationCountry": "Germany",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jan Gummert, Prof.",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          },
          {
            "LocationFacility": "University Medical Center Schleswig-Holstein",
            "LocationStatus": "Not yet recruiting",
            "LocationCity": "Lübeck",
            "LocationState": "Schleswig-Holstein",
            "LocationZip": "23562",
            "LocationCountry": "Germany",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Stephan Ensminger, Prof.",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006333",
            "ConditionMeshTerm": "Heart Failure"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8573",
            "ConditionBrowseLeafName": "Heart Failure",
            "ConditionBrowseLeafAsFound": "Heart Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}